Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2011

01-03-2011 | Article

Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products

Authors: T. M. Curtis, R. Hamilton, P.-H. Yong, C. M. McVicar, A. Berner, R. Pringle, K. Uchida, R. Nagai, S. Brockbank, A. W. Stitt

Published in: Diabetologia | Issue 3/2011

Login to get access

Abstract

Aims/hypothesis

The impact of AGEs and advanced lipoxidation end-products (ALEs) on neuronal and Müller glial dysfunction in the diabetic retina is not well understood. We therefore sought to identify dysfunction of the retinal Müller glia during diabetes and to determine whether inhibition of AGEs/ALEs can prevent it.

Methods

Sprague–Dawley rats were divided into three groups: (1) non-diabetic; (2) untreated streptozotocin-induced diabetic; and (3) diabetic treated with the AGE/ALE inhibitor pyridoxamine for the duration of diabetes. Rats were killed and their retinas were evaluated for neuroglial pathology.

Results

AGEs and ALEs accumulated at higher levels in diabetic retinas than in controls (p < 0.001). AGE/ALE immunoreactivity was significantly diminished by pyridoxamine treatment of diabetic rats. Diabetes was also associated with the up-regulation of the oxidative stress marker haemoxygenase-1 and the induction of glial fibrillary acidic protein production in Müller glia (p < 0.001). Pyridoxamine treatment of diabetic rats had a significant beneficial effect on both variables (p < 0.001). Diabetes also significantly altered the normal localisation of the potassium inwardly rectifying channel Kir4.1 and the water channel aquaporin 4 to the Müller glia end-feet interacting with retinal capillaries. These abnormalities were prevented by pyridoxamine treatment.

Conclusions/interpretation

While it is established that AGE/ALE formation in the retina during diabetes is linked to microvascular dysfunction, this study suggests that these pathogenic adducts also play a role in Müller glial dysfunction.
Appendix
Available only for authorised users
Literature
1.
Curtis TM, Gardiner TA, Stitt AW (2009) Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond) 23:1496–1508
2.
Antonetti DA, Barber AJ, Bronson SK et al (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55:2401–2411CrossRefPubMed
3.
Hancock HA, Kraft TW (2004) Oscillatory potential analysis and ERGs of normal and diabetic rats. Investig Ophthalmol Vis Sci 45:1002–1008CrossRef
4.
Phipps JA, Yee P, Fletcher EL, Vingrys AJ (2006) Rod photoreceptor dysfunction in diabetes: activation, deactivation, and dark adaptation. Investig Ophthalmol Vis Sci 47:3187–3194CrossRef
5.
Barber AJ, Antonetti DA, Kern TS et al (2005) The Ins2Akita mouse as a model of early retinal complications in diabetes. Investig Ophthalmol Vis Sci 46:2210–2218CrossRef
6.
Krady JK, Basu A, Allen CM et al (2005) Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54:1559–1565CrossRefPubMed
7.
Martin PM, Roon P, van Ells TK, Ganapathy V, Smith SB (2004) Death of retinal neurons in streptozotocin-induced diabetic mice. Investig Ophthalmol Vis Sci 45:3330–3336CrossRef
8.
Park SH, Park JW, Park SJ et al (2003) Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 46:1260–1268CrossRefPubMed
9.
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998) Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–791CrossRefPubMed
10.
Tatsumi Y, Kanamori A, Nagai-Kusuhara A et al (2008) Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo. Curr Eye Res 33:683–692CrossRefPubMed
11.
Bringmann A, Pannicke T, Grosche J et al (2006) Muller cells in the healthy and diseased retina. Prog Retin Eye Res 25:397–424CrossRefPubMed
12.
Gerhardinger C, Brown LF, Roy S, Mizutani M, Zucker CL, Lorenzi M (1998) Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol 152:1453–1462PubMed
13.
Li Q, Puro DG (2002) Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Investig Ophthalmol Vis Sci 43:3109–3116
14.
Pannicke T, Iandiev I, Wurm A et al (2006) Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 55:633–639CrossRefPubMed
15.
Thorpe SR, Baynes JW (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25:275–281CrossRefPubMed
16.
Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605CrossRefPubMed
17.
Gardiner TA, Anderson HR, Stitt AW (2003) Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol 201:328–333CrossRefPubMed
18.
Stitt AW, Hughes SJ, Canning P et al (2004) Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 47:1735–1746CrossRefPubMed
19.
Yong PH, Zong H, Medina R, et al. (2010) The \( {N^{\varepsilon }} \)-(3-formyl-3,4-dehydropiperidino)lysine adduct plays an important role in Müller glia dysfunction and death in diabetic retinopathy. Mol Vis (in press)
20.
Feit-Leichman RA, Kinouchi R, Takeda M et al (2005) Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes. Investig Ophthalmol Vis Sci 46:4281–4287CrossRef
21.
Nagai R, Horiuchi S, Unno Y (2003) Application of monoclonal antibody libraries for the measurement of glycation adducts. Biochem Soc Trans 31:1438–1440CrossRefPubMed
22.
Uchida K, Kanematsu M, Sakai K et al (1998) Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 95:4882–4887CrossRefPubMed
23.
Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW (2007) Inhibition of advanced glycation and absence of galectin-3 prevent blood–retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007:51837PubMed
24.
Stitt A, Gardiner TA, Alderson NL et al (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826–2832CrossRefPubMed
25.
Cukiernik M, Mukherjee S, Downey D, Chakabarti S (2003) Heme oxygenase in the retina in diabetes. Curr Eye Res 27:301–308CrossRefPubMed
26.
Hammes HP, Bartmann A, Engel L, Wulfroth P (1997) Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine. Diabetologia 40:629–634CrossRefPubMed
27.
Ulyanova T, Szel A, Kutty RK et al (2001) Oxidative stress induces heme oxygenase-1 immunoreactivity in Muller cells of mouse retina in organ culture. Investig Ophthalmol Vis Sci 42:1370–1374
28.
Ishii M, Horio Y, Tada Y et al (1997) Expression and clustered distribution of an inwardly rectifying potassium channel, KAB-2/Kir4.1, on mammalian retinal Muller cell membrane: their regulation by insulin and laminin signals. J Neurosci 17:7725–7735PubMed
29.
Nagelhus EA, Veruki ML, Torp R et al (1998) Aquaporin-4 water channel protein in the rat retina and optic nerve: polarized expression in Muller cells and fibrous astrocytes. J Neurosci 18:2506–2519PubMed
30.
Mohamed Q, Wong TY (2008) Emerging drugs for diabetic retinopathy. Expert Opin Emerg Drugs 13:675–694CrossRefPubMed
31.
Bhatwadekar A, Glenn JV, Figarola JL et al (2008) A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 92:545–547CrossRefPubMed
32.
Hammes HP, Du X, Edelstein D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294–299CrossRefPubMed
33.
Obrosova IG, Fathallah L, Greene DA (2000) Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur J Pharmacol 398:139–146CrossRefPubMed
34.
Zhang X, Lai Y, McCance DR et al (2008) Evaluation of \( {N^{\varepsilon }} \)-(3-formyl-3, 4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy. Diabetologia 51:1723–1730CrossRefPubMed
35.
Alderson NL, Chachich ME, Youssef NN et al (2003) The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123–2133CrossRefPubMed
36.
Alderson NL, Chachich ME, Frizzell N et al (2004) Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat. Diabetologia 47:1385–1395CrossRefPubMed
37.
Metz TO, Alderson NL, Thorpe SR, Baynes JW (2003) Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 419:41–49CrossRefPubMed
38.
Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW (2003) Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem 278:42012–42019CrossRefPubMed
39.
Vicente Miranda H, Outeiro TF (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 221:13–25CrossRefPubMed
40.
Agardh E, Bruun A, Agardh CD (2001) Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes. Curr Eye Res 23:276–284CrossRefPubMed
41.
Izumi Y, Kirby CO, Benz AM, Olney JW, Zorumski CF (1999) Muller cell swelling, glutamate uptake, and excitotoxic neurodegeneration in the isolated rat retina. Glia 25:379–389CrossRefPubMed
42.
Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M (2003) A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52:506–511CrossRefPubMed
43.
Newman EA, Frambach DA, Odette LL (1984) Control of extracellular potassium levels by retinal glial cell K+ siphoning. Science (New York, NY) 225:1174–1175CrossRef
44.
Hasegawa H, Ma T, Skach W, Matthay MA, Verkman AS (1994) Molecular cloning of a mercurial-insensitive water channel expressed in selected water-transporting tissues. J Biol Chem 269:5497–5500PubMed
45.
Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP (1997) Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17:171–180PubMed
46.
Iandiev I, Pannicke T, Reichenbach A, Wiedemann P, Bringmann A (2007) Diabetes alters the localization of glial aquaporins in rat retina. Neurosci Lett 421:132–136CrossRefPubMed
Metadata
Title
Müller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products
Authors
T. M. Curtis
R. Hamilton
P.-H. Yong
C. M. McVicar
A. Berner
R. Pringle
K. Uchida
R. Nagai
S. Brockbank
A. W. Stitt
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1971-x

Other articles of this Issue 3/2011

Diabetologia 3/2011 Go to the issue

Short Communication

Cardiovascular disease, heart failure, chronic kidney disease and depression independently increase the risk of incident diabetes

Article

Mafa expression enhances glucose-responsive insulin secretion in neonatal rat beta cells

Article

Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial

Article

Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure

Article

Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes

Short Communication

Cardiovascular risk factors in children exposed to maternal diabetes in utero
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits